Citigroup Maintains Buy on GoodRx Holdings, Lowers Price Target to $4.5
Benzinga Newsdesk 10 months ago
NewsPrice TargetAnalyst Ratings
Citigroup analyst Daniel Grosslight maintains GoodRx Holdings (NASDAQ:GDRX) with a Buy and lowers the price target from $5 to $4.5.
Citigroup analyst Daniel Grosslight maintains GoodRx Holdings (NASDAQ:GDRX) with a Buy and lowers the price target from $5 to $4.5.